olodaterol hydrochloride + tiotropium bromide monohydrate: clinical use

Prescribing considerations

• Confirm COPD and that long-acting maintenance bronchodilation is intended; not for asthma or acute symptom relief.
• Assess inhaler suitability, demonstrate Respimat technique and reassess technique and adherence if symptom control is poor.
• Use particular caution with significant cardiovascular disease, arrhythmia, QT prolongation, thyrotoxicosis, seizure disorders, diabetes or planned anaesthesia with halogenated agents.
• In moderate-to-severe renal impairment, use only where expected benefit outweighs risk because systemic tiotropium exposure increases.
• Avoid duplication with another long-acting beta₂ agonist or anticholinergic bronchodilator.

Contraindications and cautions

• Hypersensitivity to tiotropium, olodaterol or any listed excipient.
• History of hypersensitivity to atropine or atropine derivatives such as ipratropium or oxitropium.
• Use caution rather than treating as an absolute contraindication in narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction.

Monitoring

• Review COPD symptoms, functional limitation, exacerbations and use of rescue treatment.
• Check inhaler technique, device preparation and adherence.
• Ask about dry mouth, dental problems, urinary retention, constipation and ocular symptoms.
• Assess pulse, blood pressure and cardiac symptoms where clinically indicated.
• Consider potassium, glucose, ECG and renal-function assessment in susceptible patients or when interacting medicines are used.

Clinical pharmacology

Tiotropium is a long-acting muscarinic receptor antagonist; olodaterol is a long-acting beta₂-adrenoceptor agonist. Their distinct receptor actions produce additive bronchodilation. Tiotropium is predominantly eliminated renally, while olodaterol undergoes substantial hepatic metabolism.

Formulation and product differences

• The selected product is a clear, colourless inhalation solution in a replaceable cartridge for the reusable Respimat soft-mist inhaler.
• The formulation contains benzalkonium chloride, which can cause wheezing or bronchospasm in susceptible people.
• The cartridge is device-specific and must not be used independently or with another inhaler.

Inhaled preparation

Route: Inhaled

Strengths: 2.5 micrograms + 2.5 micrograms